WallStSmart

ICZOOM Group Inc. Class A Ordinary Shares (IZM)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 38% more annual revenue ($258.90M vs $187.05M). IZM leads profitability with a 0.6% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

IZM

Hold

39

out of 100

Grade: F

Growth: 3.3Profit: 4.0Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: 5.27

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for IZM.

ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IZM3 strengths · Avg: 10.0/10
P/E RatioValuation
3.4x10/10

Attractively priced relative to earnings

Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
5.2710/10

Safe zone — low bankruptcy risk

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

IZM4 concerns · Avg: 3.0/10
Market CapQuality
$4.12M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
7.8%3/10

ROE of 7.8% — below average capital efficiency

Profit MarginProfitability
0.6%3/10

0.6% margin — thin

Operating MarginProfitability
0.5%3/10

Operating margin of 0.5%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : IZM

The strongest argument for IZM centers on P/E Ratio, Price/Book, Altman Z-Score.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : IZM

The primary concerns for IZM are Market Cap, Return on Equity, Profit Margin. Thin 0.6% margins leave little buffer for downturns.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

IZM profiles as a value stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor ELECTRONICS & COMPUTER DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 39/100) and 43.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ICZOOM Group Inc. Class A Ordinary Shares

TECHNOLOGY · ELECTRONICS & COMPUTER DISTRIBUTION · China

ICZOOM Group Inc., sells electronic component products to customers in the People's Republic of China. The company is headquartered in Shenzhen, the People's Republic of China.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?